NCT06530849View on ClinicalTrials.gov

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
Refractory Systemic Lupus Erythematosus
Interventions
DRUG

GC012F Injection

GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19

Trial Locations (2)

430060

RECRUITING

Research Site, Wuhan

Unknown

RECRUITING

Research Site, Shanghai

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Suzhou Gracell Biotechnologies Co., Ltd.

UNKNOWN

lead

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY